Form 4: Praxis Precision Medicines Director Granted Stock Options Valued at $44.04 Per Share

Jeffrey Chodakewitz, a Director at Praxis Precision Medicines, Inc. (PRAX), was granted 10,520 stock options with an exercise price of $44.04 per share, vesting over one year.

Summary

• Jeffrey Chodakewitz, a Director of Praxis Precision Medicines, Inc. (PRAX), was granted 10,520 stock options.
• The stock options have an exercise price of $44.04 per share.
• The options were granted on June 26, 2025.
• The shares subject to this option will vest in twelve equal monthly installments over one year, commencing on June 26, 2025.
• The options have an expiration date of June 26, 2035.
• Following this transaction, Mr. Chodakewitz directly beneficially owns 10,520 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. It's a routine compensation event, not indicative of major operational changes.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard form of compensation for directors, indicating normal corporate governance practices.

Future Outlook

The stock options granted to Director Jeffrey Chodakewitz are set to vest in twelve equal monthly installments over one year, commencing on June 26, 2025, indicating a future increase in his beneficial ownership of company stock as the options vest.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages designed to align leadership incentives with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across publicly traded companies, including those in the biotech sector like Praxis Precision Medicines.
• While the specific number of options (10,520) and exercise price ($44.04) are unique to this grant, the structure of vesting over one year is a common approach to retain and incentivize directors.

Corporate Governance

Related Party Transactions

• The grant of stock options to Jeffrey Chodakewitz, a Director, constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of stock options to a director is intended to align the director's financial incentives with shareholder interests, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will begin vesting in twelve equal monthly installments starting June 26, 2025, over the subsequent year.

Key Dates

Keywords

Praxis Precision Medicines, PRAX, Stock Option, Director Compensation, Insider Transaction, Form 4, Equity Grant